Date: June 06, 2018 - June 06, 2018
Place: Milan

The Commission on Life Science



The Commission on Life Science will meet on June 6, 2018, to select the winning proposal from among ten finalists.


The startups selected to participate in UniCredit Start Lab 2018 will receive:


  • customized banking advice from a UniCredit manager

  • guidance from professional mentors, consultants and entrepreneurs, who will help them develop their businesses by offering skills and providing access to networks

  • management training for both domestic and international operations through UniCredit's Startup Academy

  • introductions to potential investors, in case some requirements are reached


The winner will also receive a cash prize of €10,000.


The ten finalists are as follows:


BPCOMEDIA - a company that has produced a patented medical device for measuring the health's state of patients suffering from Chronic Obstructive Pulmonary disease (COPD), capable to detect the onset of flare-ups and critical clinical situations. It highlights prognostic symptoms that patients are not able to perceive and prompts them to contact their doctor in order to receive an early treatment and avoid potential dangerous situations before symptoms appear


CHEMICARE - a new series of patented molecules, already tested, for the treatment of rare and extremely rare diseases that arise in neonatal or child age and which involve serious platelet dysfunctions, thrombotic hemorrhagic disorders, and muscular disorders, myopathies and dysplasias


INTELLIGENZA TRASPARENTE - a company that manufactures patented, ultrasound transparent and real-time personalized neurosurgical prostheses that allow the use of ultrasonography for diagnosis and HIFU for oncological treatment


ITAMPHARMA - a startup company developing a patented platform of new therapeutic systems (TAM) for the treatment of the so-called "orphan" tumors, such as the triple negative breast cancer. It is an innovative platform because it uniquely combines selectivity towards cancer cells with superior efficacy where, to date, the current therapies fail


I - VASC - an innovative patented device, composed of catheter and handpiece, for the minimally invasive, endovascular treatment of varicose veins of the lower limbs using the method of sclerotherapy, chemical ablation


MATERIAS - a company that has developed a patented technology for the production of biocompatible and / or biodegradable polymeric micro needles for transdermal administration of drugs


µERYLŌ - a new patented device that uses red blood cells as vectors for patient-specific anticancer drugs. It provides an innovative approach to the encapsulation of the drug in red blood cells, which allows the use of the device in line with the patient


NANOMNIA - The company has developed a biotech platform based on encapsulation in organic nanoparticles, which allows selective transport of active compounds in the targeted biological system, in order to increase the efficacy and specificity in delivery of drug, agrochemicals, cosmetics and food supplement


PROMETHEUS - a company that creates three-dimensional human and animal tissues that can be used in pharmacological tests and in transplants. The first product already developed and patented is a second skin for the regeneration of chronic wounds. Employable immediately in the veterinary sector and in the future in the human field for the treatment of ulcers, bedsores and severe burns


REACT4LIFE - an innovative high-tech patented device, able of emulating small portions of the human body in laboratory, where it is possible to grow physiologically relevant organ/disease models to improve the laboratory and pharmaceutical efficacy tests, to test drugs and innovative therapeutic approaches and reduce costs and time of preclinical testing, with a cruelty free approach


Stay tuned to find out who wins!



Visual LS